Home › Acute Biphenotypic Leukemia › Tennessee
Acute Biphenotypic Leukemia clinical trials in Tennessee
10 studies for Acute Biphenotypic Leukemia are looking for participants at sites in Tennessee.
Cities in Tennessee
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- The Children's Hospital at TriStar Centennial, Nashville
- and 1 more
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- T C Thompson Children's Hospital, Chattanooga
- East Tennessee Childrens Hospital, Knoxville
- The Children's Hospital at TriStar Centennial, Nashville
- and 1 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- The Children's Hospital at TriStar Centennial, Nashville
- and 1 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- St. Jude Children's Research Hospital, Memphis
RecruitingPhase 2
Ages 1 to 18 · All sexes · Updated Aug 10, 2026 · NCT06390319Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- St. Jude Children's Research Hospital, Memphis
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Aug 3, 2026 · NCT06177067Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
- St. Jude Children's Research Hospital, Memphis
RecruitingPhase 4
Ages 1 to 18 · All sexes · Updated Jul 14, 2026 · NCT06289673Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Vanderbilt University, Ingram Cancer Center, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- St. Jude Children's Research Hospital, Memphis
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.